A new trading day began on Tuesday, with Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) stock price up 3.80% from the previous day of trading, before settling in for the closing price of $18.95. ARCT’s price has ranged from $17.52 to $45.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 310.16% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -227.38%. With a float of $24.73 million, this company’s outstanding shares have now reached $26.83 million.
In an organization with 180 employees, it is important to assess its efficiency.
Arcturus Therapeutics Holdings Inc (ARCT) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcturus Therapeutics Holdings Inc is 8.53%, while institutional ownership is 95.70%. The most recent insider transaction that took place on Jun 12 ’24, was worth 1,601,500. In this transaction Chief Financial Officer of this company sold 50,000 shares at a rate of $32.03, taking the stock ownership to the 220,526 shares. Before that another transaction happened on Jun 05 ’24, when Company’s Chief Scientific Officer & COO sold 114 for $45.00, making the entire transaction worth $5,130. This insider now owns 447,334 shares in total.
Arcturus Therapeutics Holdings Inc (ARCT) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -227.38% per share during the next fiscal year.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Trading Performance Indicators
Here are Arcturus Therapeutics Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.57, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -2.05 in one year’s time.
Technical Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.5 million. That was inferior than the volume of 0.51 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 18.79%. Additionally, its Average True Range was 1.75.
During the past 100 days, Arcturus Therapeutics Holdings Inc’s (ARCT) raw stochastic average was set at 7.05%, which indicates a significant decrease from 25.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.90% in the past 14 days, which was lower than the 87.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.58, while its 200-day Moving Average is $29.22. However, in the short run, Arcturus Therapeutics Holdings Inc’s stock first resistance to watch stands at $20.18. Second resistance stands at $20.69. The third major resistance level sits at $21.45. If the price goes on to break the first support level at $18.91, it is likely to go to the next support level at $18.15. The third support level lies at $17.64 if the price breaches the second support level.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Key Stats
With a market capitalization of 531.88 million, the company has a total of 26,932K Shares Outstanding. Currently, annual sales are 166,800 K while annual income is -29,730 K. The company’s previous quarter sales were 49,860 K while its latest quarter income was -17,220 K.
